Literature DB >> 20647527

When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy.

Andrew Nicolson1, Anthony G Marson.   

Abstract

Juvenile myoclonic epilepsy is one of the most common types of epilepsy seen in an adult epilepsy clinic. Most patients have a good prognosis, particularly when treated with valproate, but a significant minority are more difficult to treat. In this article, we will focus on a management strategy when the initial antiepileptic drug is unsuccessful and outline an approach that translates directly to the clinic.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20647527     DOI: 10.1136/jnnp.2010.217976

Source DB:  PubMed          Journal:  Pract Neurol        ISSN: 1474-7758


  6 in total

Review 1.  Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential.

Authors:  Anna Serafini; Elizabeth Gerard; Pierre Genton; Arielle Crespel; Philippe Gelisse
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

2.  Treating patients with medically resistant epilepsy.

Authors:  Gregory L Krauss; Michael R Sperling
Journal:  Neurol Clin Pract       Date:  2011-12

3.  Using common genetic variants to find drugs for common epilepsies.

Authors:  Nasir Mirza; Remi Stevelink; Basel Taweel; Bobby P C Koeleman; Anthony G Marson
Journal:  Brain Commun       Date:  2021-12-04

4.  The adolescent or adult with generalized tonic-clonic seizures.

Authors:  Roop Gursahani; Namit Gupta
Journal:  Ann Indian Acad Neurol       Date:  2012-04       Impact factor: 1.383

5.  Absence Seizures as a Feature of Juvenile Myoclonic Epilepsy in Rhodesian Ridgeback Dogs.

Authors:  F Wielaender; F M K James; M A Cortez; G Kluger; J N Neßler; A Tipold; H Lohi; A Fischer
Journal:  J Vet Intern Med       Date:  2017-11-30       Impact factor: 3.333

6.  Refractory juvenile myoclonic epilepsy: a meta-analysis of prevalence and risk factors.

Authors:  R Stevelink; B P C Koeleman; J W Sander; F E Jansen; K P J Braun
Journal:  Eur J Neurol       Date:  2018-10-07       Impact factor: 6.089

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.